Meta-analysis quantifies weight loss with newer GLP-1 agents in adults without diabetes

A systematic review updating earlier evidence on GLP-1 receptor agonists and co-agonists for weight management found that newer drugs produce substantially larger weight losses than first-generation agents in adults without diabetes ^[1]. The analysis, rated as high-quality evidence, pooled data from randomized controlled trials and is described in Annals of Internal Medicine ^[1].

The review found that higher doses of subcutaneous and oral semaglutide, the active ingredient in Ozempic, Wegovy, and Rybelsus, were linked to greater weight loss than lower doses ^[1]. Tirzepatide, sold as Mounjaro and Zepbound, continued to show substantial weight reductions across the trials examined ^[1]. By contrast, liraglutide, an older GLP-1 drug, produced more modest effects ^[1]. Several premarket therapies not yet available to US patients, including drugs that target both the GLP-1 and amylin pathways, also showed substantial weight loss in the pooled data ^[1].

Beyond weight, the newer agents produced consistent, dose-dependent reductions in body mass index and waist circumference ^[1]. Effects on blood pressure were more variable across trials ^[1]. In head-to-head studies included in the review, tirzepatide and the experimental drug CagriSema produced greater weight loss than semaglutide ^[1].

On safety, gastrointestinal side effects were common across the GLP-1 class but were generally described as mild to moderate and tied to dose escalation ^[1]. Overall discontinuation because of side effects was generally uncommon, though the review noted higher discontinuation rates with newer oral nonpeptide agents ^[1]. The authors cautioned that heterogeneity in trial design, dosing schedules, and study duration, along with the enrollment of mixed populations that sometimes included people with type 2 diabetes, limits how directly the drugs can be compared to one another ^[1].

Why it matters for patients

This review does not introduce a new drug or approval. Instead, it pulls together existing trial data to show a pattern that patients and clinicians have increasingly discussed: the efficacy gap between older GLP-1 drugs like liraglutide and newer options like semaglutide and tirzepatide appears to be widening, based on pooled trial results ^[1].

For someone weighing options, this means the drug's generation and dose may matter as much as the fact that it is a "GLP-1 medication." Higher-dose semaglutide and tirzepatide were tied to larger reductions in weight, BMI, and waist size than lower doses or liraglutide, though the review stops short of saying one drug is proven better than another in a strict head-to-head sense outside the specific trials where that comparison was made directly, such as with tirzepatide and CagriSema against semaglutide ^[1].

The gastrointestinal side effects that come with these drugs, and their link to how fast doses are increased, is also relevant for anyone starting treatment, since slower or more cautious dose escalation is a routine part of how these drugs are typically managed ^[1]. The higher discontinuation rates seen with newer oral nonpeptide agents in this review is a detail worth knowing, though the source does not identify which specific drug that finding applies to ^[1].

It is also worth noting that some drugs discussed in the review, including CagriSema, are not currently approved or available in the United States, so any findings about them describe research results only, not real-world treatment options ^[1].

What happens next

The review itself does not set out specific regulatory or clinical practice dates. It is not yet known from this source whether the findings will prompt updated treatment guidelines or further comparative trials among newer agents ^[1].